Hypothalamic damage disrupts hunger and satiety regulation, causing rapid weight gain, which often responds poorly to ...

Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

Hypothalamic obesity (HyOb) develops when brain damage or conditions like Prader-Willi syndrome disrupt the hypothalamus, impairing hunger and energy regulation. Traditional calorie-based weight-loss ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

MC4R pathway restoration with daily subcutaneous setmelanotide achieved a −16.5% least-squares mean BMI change versus +3.3% with placebo at 52 weeks (P < .001). Clinically relevant response rates ...

New research reveals how extracellular matrix (ECM) buildup in the brain’s hypothalamus leads to insulin resistance, paving the way for innovative therapies targeting obesity and diabetes. Study: ...

Ovulatory dysfunction, including Polycystic ovary syndrome (PCOS) are among the most common causes of infertility in women. Caused by problems with the regulation of reproductive hormones, ovulation ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI ...